Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.

<h4>Background</h4>Despite advances in treatments for Hodgkin's lymphoma, about 20% of patients still die from progressive disease. Current prognostic models predict the outcome of treatment with imperfect accuracy, and clinically relevant biomarkers have not been established to improve on the Inter... View More